GO:0015820 L-leucine transport: Amino Acid Transport Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0015820 L-leucine transport describes the directed movement of L-leucine into, out of, or within cells via transporters or pores.
• L-leucine is a branched-chain essential amino acid and a key activator of mTORC1 signaling, making its transport critical for cell growth and metabolism.
• Multiple transport systems exist, including sodium-dependent and sodium-independent carriers, with distinct kinetics in different tissues.
• LAT1 (SLC7A5) and LAT2 (SLC7A8) are major heterodimeric amino acid exchangers mediating L-leucine transport in cancer, kidney, and blood-retinal barrier.
• Dysregulated L-leucine transport is implicated in cancer metabolism, neurological disorders, and metabolic diseases.
• CRISPR knockout, knock-in, and overexpression models enable functional dissection of L-leucine transporters in health and disease.
Description
L-leucine transport (GO:0015820) is the biological process by which the essential amino acid L-leucine is moved across cellular membranes by dedicated transporter proteins or pores. Because L-leucine cannot be synthesized by mammals, its uptake from the extracellular environment is obligatory for protein synthesis and for activation of the mTORC1 nutrient-sensing pathway. The process is mediated by a diverse set of transport systems that differ in tissue distribution, substrate specificity, sodium dependence, and kinetic properties. In the small intestine, L-leucine transport occurs via brush-border membrane carriers that also handle dipeptides such as glycyl-L-leucine. In the kidney, heterodimeric exchangers LAT1 and LAT2 mediate both high- and low-affinity L-leucine transport. In the brain, LAT1 at the inner blood-retinal barrier facilitates L-leucine delivery to the retina. Even microorganisms such as Saccharomyces cerevisiae, Halobacterium salinarum, and Pseudomonas aeruginosa possess specific L-leucine transport systems, underscoring the evolutionary conservation of this process. For researchers, GO:0015820 provides a framework to study amino acid homeostasis, nutrient signaling, and transporter pharmacology across species and disease contexts.
L-leucine transport At A Glance
| GO ID | GO:0015820 |
|---|---|
| GO term | L-leucine transport |
| Ontology | biological_process |
| Synonym | leucine transport |
| Definition | The directed movement of L-leucine, 2-amino-4-methylpentanoic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. |
| Major function | Mediates cellular uptake and distribution of the essential amino acid L-leucine for protein synthesis and mTORC1 signaling. |
| Key transporters | LAT1 (SLC7A5), LAT2 (SLC7A8), GAP1, S1, S2, and sodium-dependent systems. |
| Tissue distribution | Small intestine, kidney, blood-retinal barrier, breast, and microorganisms. |
| Disease relevance | Cancer metabolism, neurological disorders, metabolic diseases. |
What Is GO:0015820?
According to the Gene Ontology, GO:0015820 L-leucine transport is defined as the directed movement of L-leucine (2-amino-4-methylpentanoic acid) into, out of, or within a cell, or between cells, by means of some agent such as a transporter or pore. This process encompasses all mechanisms that mediate the transmembrane or transcellular flux of L-leucine, including facilitated diffusion, sodium-coupled symport, and amino acid exchange. The term is a biological_process child of amino acid transport and is distinct from the transport of D-leucine or of leucine-containing dipeptides, although these may be functionally related.
Why Is L-leucine transport Important in Cell Biology?
L-leucine transport is fundamentally important because L-leucine is an essential branched-chain amino acid that serves both as a building block for protein synthesis and as a potent activator of mTORC1, the master regulator of cell growth and proliferation. The rate of L-leucine uptake therefore directly influences translational capacity, metabolic flux, and cell fate decisions. In cancer cells, upregulated L-leucine transporters such as LAT1 support the high biosynthetic demands of rapidly dividing cells. In the kidney, LAT1 and LAT2 regulate amino acid homeostasis and drug handling. At the blood-retinal barrier, LAT1-mediated L-leucine transport is essential for retinal nutrition. Disruptions in L-leucine transport are linked to metabolic disorders, neurodegeneration, and cancer, making this process a compelling target for therapeutic intervention and a key area of biomedical research.
• L-leucine is an essential amino acid required for protein synthesis in mammals.
• L-leucine activates mTORC1 signaling, linking transport to cell growth control.
• LAT1 (SLC7A5) is overexpressed in many cancers and supports tumor growth.
• LAT2 (SLC7A8) mediates high-affinity L-leucine transport in kidney and other tissues.
• Blood-retinal barrier LAT1 transports L-leucine for retinal homeostasis.
• Intestinal L-leucine transport systems are targets for nutrient absorption studies.
• Yeast and bacterial L-leucine transporters serve as models for evolutionarily conserved mechanisms.
• Dysregulated L-leucine transport contributes to metabolic and neurological disorders.
• Transporters are potential drug targets for cancer and metabolic diseases.
• CRISPR-based models enable precise functional interrogation of L-leucine transport genes.
What Happens During L-leucine transport?
Substrate Recognition and Binding
In simple terms: The transporter first recognizes and grabs L-leucine from one side of the membrane.
L-leucine transport begins when a transporter protein binds L-leucine with stereospecificity, distinguishing it from D-leucine and other amino acids. In the archaeon Halobacterium salinarum, D-leucine and L-leucine are transported by distinct systems, indicating that recognition is enantiomer-specific. In mammalian cells, LAT1 and LAT2 recognize L-leucine as a substrate for exchange. The binding affinity varies: LAT1 and LAT2 exhibit high- and low-affinity transport modes for L-leucine in renal cells. In the small intestine, brush-border membrane vesicles from human and rabbit show specific L-leucine transport systems.
Translocation Across the Membrane
In simple terms: Once bound, the transporter moves L-leucine across the cell membrane.
After binding, the transporter undergoes conformational changes to translocate L-leucine across the lipid bilayer. In Pseudomonas aeruginosa membrane vesicles, L-leucine transport is sodium-dependent, indicating a symport mechanism. In Saccharomyces cerevisiae, GAP1, S1, and S2 transport systems participate in L-leucine uptake with different kinetic properties. In human breast cancer cells (MCF-7 and MDA-MB-231), L-leucine transport kinetics reveal specific transporter-mediated uptake that is regulated by estrogen. At the inner blood-retinal barrier, LAT1 mediates L-leucine transport, facilitating delivery from blood to retina.
Cellular Distribution and Metabolic Fate
In simple terms: After entering the cell, L-leucine is used for protein synthesis or signaling.
Once inside the cell, L-leucine can be incorporated into newly synthesized proteins or act as a signaling molecule to activate mTORC1. In intestinal epithelial cells, transported L-leucine contributes to protein synthesis and mucosal growth. In renal cells, L-leucine uptake via LAT1 and LAT2 influences intracellular amino acid pools and may affect L-DOPA handling. In yeast, transported L-leucine is used for protein synthesis and nitrogen metabolism. The ultimate fate of L-leucine depends on cellular demand and the activity of downstream metabolic pathways.
Regulation of Transport Activity
In simple terms: The cell can adjust how much L-leucine it takes up based on its needs.
L-leucine transport is regulated at multiple levels. In breast cancer cells, estrogen regulates L-leucine transport kinetics, suggesting hormonal control of transporter expression or activity. In the small intestine, transport systems are subject to developmental and dietary regulation. In yeast, the GAP1, S1, and S2 systems are differentially regulated in response to nitrogen availability. In renal cells, high- and low-affinity transport modes may reflect distinct regulatory states of LAT1 and LAT2. Such regulation ensures that L-leucine supply matches cellular demand for protein synthesis and signaling.
Integration with mTORC1 Signaling
In simple terms: L-leucine uptake feeds into a major growth-control pathway.
A key consequence of L-leucine transport is the activation of mTORC1, which promotes protein synthesis and cell growth. In breast cancer cells, L-leucine uptake is linked to estrogen-dependent growth, implicating transport in hormone-responsive tumor biology. In the retina, LAT1-mediated L-leucine transport supports the nutritional needs of retinal cells. In kidney cells, L-leucine transport via LAT1 and LAT2 may influence mTORC1 activity and cellular metabolism. Thus, L-leucine transport is not merely a nutrient uptake process but a critical node integrating extracellular amino acid availability with intracellular signaling.
Key Genes Involved in GO:0015820 L-leucine transport
The following genes and proteins are experimentally implicated in L-leucine transport (GO:0015820) based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC7A5 (LAT1) | Mediates high-affinity L-leucine transport at the blood-retinal barrier and in cancer cells | Target for cancer therapy and blood-retinal barrier studies |
| SLC7A8 (LAT2) | Mediates high- and low-affinity L-leucine transport in renal cells | Kidney amino acid homeostasis and drug transport |
| SLC3A2 (4F2hc) | Heavy chain partner for LAT1 and LAT2 heterodimeric transporters | Required for functional LAT1/LAT2 surface expression |
| GAP1 | Yeast general amino acid permease involved in L-leucine transport | Model for nitrogen-regulated amino acid uptake |
| S1 | Yeast L-leucine transport system component | Study of yeast amino acid transport specificity |
| S2 | Yeast L-leucine transport system component | Study of yeast amino acid transport specificity |
| SLC7A5/SLC3A2 complex | Heterodimeric exchanger for L-leucine and other large neutral amino acids | Structural and functional studies of amino acid exchangers |
| SLC7A8/SLC3A2 complex | Heterodimeric exchanger for L-leucine in kidney | Renal amino acid transport and drug interactions |
| Intestinal brush-border transporters | Mediate L-leucine uptake in small intestine | Nutrient absorption and oral drug delivery |
| Breast cancer cell transporters | Mediate estrogen-regulated L-leucine uptake in MCF-7 and MDA-MB-231 | Hormone-responsive cancer metabolism |
| Pseudomonas aeruginosa L-leucine transporter | Sodium-dependent L-leucine transport | Bacterial amino acid transport and pathogenesis |
| Halobacterium salinarum L-leucine transporter | Enantiomer-specific L-leucine transport | Archaeal membrane transport mechanisms |
| Glycyl-L-leucine transporter | Mediates dipeptide transport in rat small intestine | Peptide absorption and nutritional studies |
| LAT1 (SLC7A5) in retina | L-leucine transport at inner blood-retinal barrier | Retinal nutrient supply and barrier function |
| LAT2 (SLC7A8) in LLC-PK1 cells | High- and low-affinity L-leucine transport | Renal cell model for amino acid exchange |
| MCF-7 cell transporter | Estrogen-regulated L-leucine transport | Breast cancer hormone response |
| MDA-MB-231 cell transporter | L-leucine transport kinetics in triple-negative breast cancer | Cancer metabolism and transporter targeting |
How Is L-leucine transport Regulated?
L-leucine transport is regulated by hormonal, nutritional, and developmental signals. In human breast cancer cells, estrogen regulates L-leucine transport kinetics, suggesting that transporter expression or activity is under hormonal control. In the small intestine, L-leucine transport systems are subject to dietary and developmental regulation, with distinct brush-border membrane transporters in human and rabbit. In Saccharomyces cerevisiae, the GAP1, S1, and S2 transport systems are differentially regulated in response to nitrogen availability. In renal cells, high- and low-affinity transport modes of LAT1 and LAT2 may reflect distinct regulatory states. Additionally, L-leucine itself can influence mTORC1 signaling, creating a feedback loop between transport and downstream growth pathways.
L-leucine transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC7A5 (LAT1) | Cancer metabolism, retinal nutrient supply | Knockout in cancer cell lines; retinal endothelial cell models |
| SLC7A8 (LAT2) | Renal amino acid transport, drug handling | Knockout in LLC-PK1 renal cells |
| SLC3A2 (4F2hc) | Heterodimeric transporter function | Knockout in cell lines expressing LAT1/LAT2 |
| GAP1 | Yeast nitrogen metabolism | Knockout in Saccharomyces cerevisiae |
| Intestinal transporters | Malabsorption, nutrient uptake | Brush-border membrane vesicle assays; knockout mouse models |
Cancer Metabolism and L-leucine Transport
L-leucine transport is upregulated in many cancers to support rapid proliferation. In human breast cancer cells (MCF-7 and MDA-MB-231), L-leucine transport kinetics are regulated by estrogen, linking transport to hormone-responsive tumor growth. LAT1 (SLC7A5) is a major mediator of L-leucine uptake in cancer cells and is a potential therapeutic target. Because L-leucine activates mTORC1, increased transport can drive anabolic metabolism and cell growth. Targeting L-leucine transporters may therefore offer a strategy to restrict tumor nutrient supply.
Neurological and Retinal Disorders
At the inner blood-retinal barrier, LAT1-mediated L-leucine transport is essential for delivering this essential amino acid to the retina. Disruption of this transport could impair retinal function and contribute to retinal degenerative diseases. In the brain, L-leucine transport across the blood-brain barrier is critical for neurotransmitter synthesis and metabolic homeostasis, although specific disease links require further study. Understanding LAT1 function at the blood-retinal barrier may inform therapies for retinal disorders.
Metabolic and Renal Disorders
In the kidney, LAT1 and LAT2 mediate high- and low-affinity L-leucine transport, influencing amino acid homeostasis and the handling of drugs such as L-DOPA. Dysregulation of these transporters could contribute to renal aminoacidurias or drug toxicity. In the small intestine, impaired L-leucine transport may lead to malabsorption and nutritional deficiencies. Thus, L-leucine transport is relevant to metabolic and gastrointestinal disorders.
From L-leucine transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SLC7A5 (LAT1) mediate L-leucine transport in cancer cells? | CRISPR knockout of SLC7A5 in MCF-7 or MDA-MB-231 cells |
| What is the role of LAT2 in renal L-leucine transport? | Knockout of SLC7A8 in LLC-PK1 cells |
| How does estrogen regulate L-leucine transport? | Point mutation or overexpression of estrogen receptor in breast cancer cells |
| What is the function of GAP1 in yeast L-leucine uptake? | Knockout of GAP1 in Saccharomyces cerevisiae |
| Does LAT1 at the blood-retinal barrier transport L-leucine? | Knockout or knockdown in retinal endothelial cells |
| How do intestinal transporters handle L-leucine? | Knockout of candidate transporters in intestinal epithelial cells |
How to Study the L-leucine transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiolabeled L-leucine uptake | Transport rate and kinetics (Km, Vmax) | Characterizing transport systems in cells and vesicles |
| CRISPR knockout | Loss-of-function effect on L-leucine transport | Identifying essential transporters |
| RNA interference | Gene knockdown effect on transport | Validating transporter candidates |
| Immunofluorescence | Subcellular localization of transporters | Tissue-specific expression studies |
| Membrane vesicle transport assay | Sodium dependence and substrate specificity | Bacterial and intestinal transport studies |
| Pharmacological inhibition | Contribution of specific transporters | Cancer and renal transport studies |
| Overexpression | Gain-of-function transport activity | Confirming transporter identity |
| Kinetic modeling | Transport mechanism (exchange vs. symport) | Distinguishing transport modes |
Transport Kinetics Assays
Radiolabeled or fluorescent L-leucine uptake assays are used to measure transport kinetics (Km, Vmax) in cells and membrane vesicles. These assays can distinguish high- and low-affinity transport systems and assess sodium dependence. In breast cancer cells, such assays revealed estrogen-regulated L-leucine transport. In yeast, they identified GAP1, S1, and S2 systems.
Molecular Identification of Transporters
Expression cloning, RNA interference, and CRISPR knockout are used to identify the molecular identity of L-leucine transporters. For example, LAT1 and LAT2 were identified as mediators of L-leucine transport in renal cells. In breast cancer cells, the transporter responsible for L-leucine uptake was characterized kinetically and molecularly. Such approaches are essential to link transport activity to specific genes.
Imaging and Localization Studies
Immunofluorescence and immunohistochemistry localize L-leucine transporters in tissues such as the blood-retinal barrier and small intestine. These methods reveal polarized expression and membrane domain-specific transport. In the retina, LAT1 localization at the inner blood-retinal barrier was demonstrated by imaging. In intestinal brush-border membranes, transporter localization supports vectorial transport.
Genetic and Pharmacological Perturbation
CRISPR knockout, overexpression, and pharmacological inhibitors are used to dissect L-leucine transport function. Inhibitors such as BCH or JPH203 can block LAT1-mediated transport, revealing its contribution to cell growth. In yeast, gene deletion of GAP1, S1, or S2 clarifies their individual roles. These approaches link transport activity to downstream phenotypes such as mTORC1 signaling.
How CRISPR Can Be Used to Study GO:0015820 L-leucine transport
Knockout
CRISPR knockout of L-leucine transporter genes such as SLC7A5 (LAT1) or SLC7A8 (LAT2) enables loss-of-function studies to determine their contribution to cellular L-leucine uptake and downstream phenotypes. For example, knockout of SLC7A5 in breast cancer cells can reveal its role in estrogen-regulated transport and mTORC1 activation. In renal cells, knockout of SLC7A8 can dissect high- and low-affinity transport modes.
Point Mutation
CRISPR point mutation can introduce specific amino acid substitutions in transporter genes to study structure-function relationships, substrate specificity, or regulatory phosphorylation sites. For instance, mutating residues in the substrate-binding pocket of LAT1 or LAT2 can reveal determinants of L-leucine recognition. Such models are valuable for understanding transport mechanisms at the molecular level.
Knock-in
CRISPR knock-in of epitope tags or fluorescent reporters into endogenous transporter loci allows real-time tracking of L-leucine transporter expression and localization. Tagged LAT1 or LAT2 can be used to study trafficking to the plasma membrane and interactions with accessory proteins such as 4F2hc. Knock-in models also enable precise measurement of transporter abundance in different tissues.
Overexpression
CRISPR-mediated overexpression or cDNA-based overexpression of L-leucine transporters can confirm their sufficiency to mediate transport and drive downstream signaling. Overexpression of LAT1 in cancer cells enhances L-leucine uptake and mTORC1 activity, supporting its oncogenic role. In renal cells, overexpression of LAT2 can increase high-affinity transport capacity.
How EDITGENE Supports L-leucine transport Research
Researchers studying L-leucine transport-related genes often need to determine whether a candidate gene is causally involved in transport, how mutations affect transporter function, and whether targeting the gene alters disease-relevant phenotypes. EDITGENE provides comprehensive CRISPR-based services to address these questions with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for L-leucine transport research.
Frequently Asked Questions About L-leucine transport
What is L-leucine transport (GO:0015820)?
L-leucine transport is the directed movement of L-leucine into, out of, or within a cell, or between cells, by means of a transporter or pore.
What genes are involved in L-leucine transport?
Key genes include SLC7A5 (LAT1), SLC7A8 (LAT2), SLC3A2 (4F2hc), and in yeast GAP1, S1, and S2.
How is L-leucine transported across the blood-retinal barrier?
LAT1 (SLC7A5) mediates L-leucine transport at the inner blood-retinal barrier.
Is L-leucine transport sodium-dependent?
Some L-leucine transport systems are sodium-dependent, such as in Pseudomonas aeruginosa membrane vesicles, while others like LAT1/LAT2 are sodium-independent exchangers.
What is the role of LAT1 in cancer?
LAT1 mediates L-leucine uptake in cancer cells and supports mTORC1 signaling and tumor growth.
How is L-leucine transport regulated in breast cancer cells?
Estrogen regulates L-leucine transport kinetics in MCF-7 and MDA-MB-231 breast cancer cells.
What transport systems exist in yeast for L-leucine?
Saccharomyces cerevisiae uses GAP1, S1, and S2 transport systems for L-leucine uptake.
Can L-leucine transport be studied with CRISPR?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable functional studies of L-leucine transporters.
What diseases are linked to L-leucine transport?
Cancer metabolism, retinal disorders, and renal amino acid transport defects are linked to L-leucine transport.
How do intestinal cells transport L-leucine?
Brush-border membrane transporters in the small intestine mediate L-leucine uptake, with distinct systems in human and rabbit.
Conclusion
L-leucine transport (GO:0015820) is a fundamental biological process that governs the cellular uptake of an essential amino acid critical for protein synthesis and mTORC1 signaling. The diversity of transport systems, from mammalian LAT1/LAT2 to yeast GAP1 and bacterial sodium-dependent carriers, highlights the evolutionary importance of this process. Dysregulation of L-leucine transport is implicated in cancer, retinal disorders, and renal dysfunction, making it a compelling target for therapeutic development. Continued research using CRISPR-based models and advanced transport assays will further elucidate the molecular mechanisms and disease relevance of L-leucine transport.
References
- 1. Tomi M et al.. 2005. L-type amino acid transporter 1-mediated L-leucine transport at the inner blood-retinal barrier.. Invest Ophthalmol Vis Sci 46(7):2522-30 PMID: 15980244
- 2. Shennan DB et al.. 2004. L-leucine transport in human breast cancer cells (MCF-7 and MDA-MB-231): kinetics, regulation by estrogen and molecular identity of the transporter.. Biochim Biophys Acta 1664(2):206-16 PMID: 15328053
- 3. Cheeseman CI et al.. 1982. Glycyl-L-leucine transport in the rat small intestine.. Can J Physiol Pharmacol 60(9):1177-84 PMID: 7151013
- 4. Kotliar N et al.. 1994. L-leucine transport systems in Saccharomyces cerevisiae participation of GAP1, S1 and S2 transport systems.. Cell Mol Biol (Noisy-le-grand) 40(6):833-42 PMID: 7812191
- 5. Iannoli P et al.. 1999. Characterization of L-leucine transport system in brush border membranes from human and rabbit small intestine.. Metabolism 48(11):1432-6 PMID: 10582553
- 6. Soares-da-Silva P et al.. 2004. High- and low-affinity transport of L-leucine and L-DOPA by the hetero amino acid exchangers LAT1 and LAT2 in LLC-PK1 renal cells.. Am J Physiol Renal Physiol 287(2):F252-61 PMID: 15271688
- 7. Tanaka M et al.. 2000. Differential transport properties of D-leucine and L-leucine in the archaeon, Halobacterium salinarum.. Can J Microbiol 46(4):376-82 PMID: 10779875
- 8. Hoshino T et al.. 1979. Sodium-dependent transport of L-leucine in membrane vesicles prepared from Pseudomonas aeruginosa.. J Bacteriol 137(1):73-81 PMID: 83991
